PPMA Demands Increase In Drug Prices By DRA

News: The pharmaceutical industry in Pakistan opposes price controls by the Drug Regulatory Authority (DRA) and has asked for an increase in drug prices for sustainable growth, Pakistan Pharmaceutical Manufacturers Association (PPMA) chairman Jawed Akhai has said. The PPMA has demanded the end of DRA price controls over molecules that are not described as 'life saving' by the World Health Organization, the Business Recorder said. It also wants pending policy matters hampering growth of local pharmaceutical industry to resolved. Akhai urged legislators for an act of parliament that enables regional control of the healthcare sector. The DRA was also urged to streamline the drug registration process, including a set turnaround time for every application, and to help create a healthy relationship and better working conditions between the industry and the regulator. Other demands by PPMA include more employment opportunities, free medical coverage for the unemployed and underpaid, and provision of social security.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Pakistan, Pakistan, Pakistan, Pakistan

Access all of our latest analysis, data and forecasts - request a trial